NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -86.23% | 64.68% | -1.87% | -123.16% | -30.10% |
| Total Depreciation and Amortization | 292.31% | 100.00% | 46.15% | 66.67% | 198.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 789.12% | -32.17% | -106.79% | 359.51% | -40.17% |
| Change in Net Operating Assets | -185.45% | 100.48% | -587.47% | -1,647.76% | -82.53% |
| Cash from Operations | -13.32% | 73.39% | -84.20% | -71.36% | -221.51% |
| Capital Expenditure | 0.00% | -733.33% | -4,080.00% | -5,400.00% | 97.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,072,533.33% | -733.33% | -4,080.00% | -5,400.00% | 97.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -68.82% | -26.46% | 16,554.64% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -68.82% | -26.46% | 8,185.12% | -100.00% |
| Foreign Exchange rate Adjustments | -252.05% | 383.75% | 44.23% | -181.52% | 168.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,352.88% | 83.51% | -104.99% | 632.62% | -114.98% |